Article Sidebar

PDF
Date Published: 12/01/2022
Abstract Views: 271
Views PDF: 141
DOI: https://doi.org/10.51298/vmj.v509i1.1744
Issue
Vol. 509 No. 1 (2021)
Section
Các bài báo
How to Cite
Quang Trung, N. ., Vĩnh Hùng, P. ., Viết Bình, N. ., Khánh Toàn, N. ., & Thị Hường, P. . (2022). THE EFFICALLY OF MAINTANCE DOCETAXEL IN ADVANCED STAGE NON SMALL CELL LUNG CANCER AT NGHE AN ONCOLOGY HOSPITAL. Vietnam Medical Journal, 509(1). https://doi.org/10.51298/vmj.v509i1.1744

THE EFFICALLY OF MAINTANCE DOCETAXEL IN ADVANCED STAGE NON SMALL CELL LUNG CANCER AT NGHE AN ONCOLOGY HOSPITAL

Nguyễn Quang Trung1, Phạm Vĩnh Hùng1, Nguyễn Viết Bình1, Nguyễn Khánh Toàn1, Phạm Thị Hường1,
1 Nghe An Oncology Hospital

Main Article Content

Abstract

Objective: Effect and side effect of  maintance Docetaxel in advance stage non-small cell lung cancer. Patients and method of study: Retrospective and prospective study on 47 non-small cell lung cancer patients in advanced stage after first- line treatmentdouble- platinum chemotherapy from January 2016 to August 2020. Results: Median of age 62,5 ± 7,06; Male/Female:3,7/1. A patient completely responded (2,3%), 34% partial respone, stable disease rate 38,3%. Mean Progression free survival 9.0± 0.4  months, overal survival 18,7 months. Side effects: anemia 78,7%, neutropenia 46,7%, transaminase elevation 21,3%, nausea and vomiting (27,6%). Almost side effects are grade 1 – 2.

Article Details

Keywords

Advance stage Non small cell lung cancer, Maintance docetaxel

References

1. International Agency for Research on Cancer (2012). Estimated Cancer Incidence, Mortality and Prevalence Worldwide 2012.
2. Bùi Diệu, Nguyễn Bá Đức, Trần Văn Thuấn (2010). Tình hình mắc ung thư tại Việt Nam 2004-2008 qua số liệu của 6 vùng. Tạp chí ung thư học Việt Nam, 1/2010, 75-77.
3. Coate LE, Shepherd FA. Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes. Ther Adv Med Oncol. 2011;3(3):139-157. doi:10.1177/1758834011399306
4. Nguyễn Bá Đức, Bùi Công Cường, Trần Văn Thuấn (2007). Ung thư phổi. Chẩn đoán và điều trị bệnh ung thư, 176-187.
5. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012; 13:247.
6. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:591.
7. Lã Duy Tuyến (2019). Đánh giá hiệu quả điều trị duy trì Pemetrexed trong ung thư phổi không tế bào nhỏ, không vảy giai đoạn muộn sau điều trị hóa chất bước 1 Pemetrexed – cisplatin. Tạp chí ung thư học Việt Nam.
8. Li, P., et al. (2013). "Different-dose docetaxel plus cisplatin as first-line chemotherapy and then maintenance therapy with single-agent docetaxel for advanced non-small cell lung cancer (TFINE study, C-TONG 0904)." Journal of Clinical Oncology 31: 8015-8015.